Merck, Moderna launch Phase 3 trial evaluating adjuvant V940, Keytruda combo

Merck (MRK) and Moderna (MRNA) announced the initiation of INTerpath-009, a pivotal Phase 3 randomized clinical trial evaluating V940, an investigational individualized neoantigen therapy, in combination with Keytruda, Merck’s anti-PD-1 therapy, as adjuvant treatment for patients with resectable Stage II, IIIA or IIIB non-small cell lung cancer who did not achieve a pathological complete response after receiving neoadjuvant Keytruda plus platinum-based chemotherapy. Global recruitment in INTerpath-009 has begun, and the first patients have now started enrolling in Canada.